Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376477 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03376477 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants.
The verdict
NCT03376477, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).
Interventions
- DRUG Lenalidomide
- BIOLOGICAL GM-CSF vaccine
- DRUG Prevnar13
- OTHER Placebo Prevnar13
- OTHER Placebo GM-CSF Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03376477
The ClinicalTrials.gov registry entry for NCT03376477 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lenalidomide is the first listed.
NCT03376477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03376477 about?
NCT03376477 is a clinical study titled "Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission". This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this stud...
What is the current status of trial NCT03376477?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-09-23. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT03376477?
The interventions under investigation include: Lenalidomide (DRUG), GM-CSF vaccine (BIOLOGICAL), Prevnar13 (DRUG), Placebo Prevnar13 (OTHER), Placebo GM-CSF Vaccine (OTHER).
Who is sponsoring clinical trial NCT03376477?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.